Just – Evotec Biologics
Just – Evotec Biologics is a CDMO subsidiary of Evotec SE providing development and continuous manufacturing services for antibody, next-generation biologics, and biosimilar products from two Seattle-area facilities.
- Company typePrivate
- Founded-
- Headquarters—
- Headcount—
- GTM typeB2B
- OfferingServices
What Just – Evotec Biologics does
Just – Evotec Biologics is a contract development and manufacturing organization (CDMO) that provides development and cGMP manufacturing services for antibody, next-generation biologics, and biosimilar products. The company operates as a wholly-owned subsidiary of Evotec SE, a publicly traded German biotechnology company listed on the Frankfurt Stock Exchange, and serves pharmaceutical and biotechnology clients across the full biologics development lifecycle, from antibody discovery and cell line development through clinical and commercial manufacturing. Its primary customer segment is pharma and biotech firms requiring flexible, scalable biologics manufacturing capacity, with particular emphasis on complex molecules such as bispecifics and monoclonal antibodies.
The company's core technological differentiator is an integrated end-to-end continuous manufacturing platform that uses perfusion cell culture bioreactors to continuously purify antibodies and recombinant proteins. This platform is housed within J.POD, an award-winning modular clean room facility design that materially reduces plant footprint, capital intensity, and construction timeline relative to traditional stainless-steel batch facilities. Each J.POD facility is reported to produce up to two metric tons of product per year despite its compact size. The service portfolio includes mAbs Optimization Solutions, Cell Line Development Solutions, CHO Perfusion Cell Culture Medium as a specialty input, and Clinical Stage cGMP Manufacturing services, all delivered from two co-located manufacturing sites in Seattle and Redmond, Washington.
Just – Evotec Biologics generates revenue through three primary streams: traditional CDMO fee-for-service engagements, co-development and integrated strategic partnerships, and technology out-licensing of its continuous manufacturing platform. Its go-to-market motion is enterprise field sales targeting pharmaceutical and biotechnology companies, with services sold on a project-specific, quote-based pricing model. The stated strategic mission centers on reducing cost of goods and expanding global access to affordable, high-quality biotherapeutics, with the J.POD design positioned as a replicable, lower-capital manufacturing architecture suited to emerging-market deployment.
Just – Evotec Biologics firmographics
Firmographics- Name
- Just – Evotec Biologics
- Legal name
- Just - Evotec Biologics
- Website
- https://just-evotecbiologics.com
- Company type
- Private
- Operating status
- Operating
- Short description
- Just – Evotec Biologics is a CDMO subsidiary of Evotec SE providing development and continuous manufacturing services for antibody, next-generation biologics, and biosimilar products from two Seattle-area facilities.
- Ownership category
- akta.pro rank
Just – Evotec Biologics industry classification
Industry- Product category
- Biologics Contract Development and Manufacturing (CDMO)
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Biologics (mAbs/Recombinant Proteins) CDMO (HLAGABAC)
- akta.pro secondary industry
- Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK)
Keywords
Just – Evotec Biologics business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales
Revenue model
- CDMO Fee-for-Service: Traditional CDMO fee-for-service approaches for development and cGMP manufacturing services for antibody, next-generation biologics, and biosimilar products including cell line development, analytical services, process development, and clinical to commercial manufacturing.
- Co-development and Strategic Partnerships: Co-development and integrated programs with clients on antibody discovery, development, and biomanufacturing projects, providing deeper strategic collaboration beyond traditional fee-for-service.
- Technology Out-Licensing: Technology out-licensing opportunities for their continuous manufacturing technologies and platform capabilities.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels2 records
Just – Evotec Biologics product offering
Product offeringCore offering
Just – Evotec Biologics is a biologics CDMO that provides development and cGMP manufacturing services for antibody, next-generation biologics, and biosimilar products. Its integrated end-to-end continuous manufacturing platform uses perfusion cell culture bioreactors to continuously purify antibodies and recombinant proteins, and is housed within J.POD, an award-winning modular clean room pod facility design that delivers high product quality in a compact footprint capable of producing up to two metric tons per year.
Product overview
Just – Evotec Biologics operates as a CDMO (Contract Development and Manufacturing Organization) offering an integrated platform of services for biologics development and manufacturing. The core offering centers on an end-to-end continuous manufacturing platform that enables continuous purification of antibodies and recombinant proteins from perfusion cell culture bioreactors. This platform is housed within J.POD, the company's award-winning modular clean room facility design. The portfolio includes complementary service offerings: Cell Line Development Solutions for creating high-producing cell lines; CHO Perfusion Cell Culture Medium as a specialized input product; mAbs Optimization Solutions for enhancing antibody properties; and Clinical Stage cGMP Manufacturing services spanning early clinical through commercial production. The company operates two manufacturing sites in Seattle and Redmond, WA, offering all services under one roof from discovery through commercial manufacturing.
Differentiator
Problem solved
Functional benefit
Products and services
- mAbs Optimization Solutions Monoclonal antibody (mAb) optimization services designed to enhance antibody properties including affinity, stability, and expression levels for pharmaceutical and biotech clients.
- Clinical Stage cGMP Manufacturing cGMP biologics manufacturing services spanning early clinical through commercial production, using continuous bioprocessing technology for antibody, next-generation biologics, and biosimilar products.
- Cell Line Development Solutions Development services for high-producing cell lines optimized for antibody and recombinant protein expression.
- CHO Perfusion Cell Culture Medium Specialized cell culture medium formulated for CHO (Chinese Hamster Ovary) perfusion cell culture processes, sold as a standalone input product for biologics manufacturing.
- End-to-End Continuous Manufacturing Platform Integrated continuous manufacturing process platform that continuously purifies antibodies and recombinant proteins from perfusion cell culture bioreactors, enabling higher product quality in a smaller manufacturing footprint; offered for technology out-licensing in addition to internal CDMO use.
Quantifiable outcome
- Up to 2 metric tons of product per year from small footprint J.POD facilities
- +1 more outcomes
Companies that use Just – Evotec Biologics
Customer profileSegments1 record
Ideal customer profiles1 record
Just – Evotec Biologics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Just – Evotec Biologics partnerships and signals
Strategic signalScale indicators3 records
Recent moves5 records
Expansion highlights4 records
Just – Evotec Biologics competitors and assessment
Company assessmentMarket position
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
Just – Evotec Biologics social profiles
Digital presenceJust – Evotec Biologics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Just – Evotec Biologics leadership team
Management profileNumber of profiles
Just – Evotec Biologics funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Just – Evotec Biologics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Just – Evotec Biologics
What does Just – Evotec Biologics do?
Just – Evotec Biologics is a biologics CDMO that provides development and cGMP manufacturing services for antibody, next-generation biologics, and biosimilar products. Its integrated end-to-end continuous manufacturing platform uses perfusion cell culture bioreactors to continuously purify antibodies and recombinant proteins, and is housed within J.POD, an award-winning modular clean room pod facility design that delivers high product quality in a compact footprint capable of producing up to two metric tons per year.
Is Just – Evotec Biologics a public or private company?
Just – Evotec Biologics is a private company. It is classified as corporate owned and is currently operating.
When was Just – Evotec Biologics founded?
Just – Evotec Biologics was founded in -1.
How does Just – Evotec Biologics make money?
Three revenue lines are on record. CDMO Fee-for-Service is the primary driver. The others are co-development and Strategic Partnerships and technology Out-Licensing.
Does Just – Evotec Biologics have an API?
No public API is recorded for Just – Evotec Biologics.
What industry is Just – Evotec Biologics in?
Just – Evotec Biologics's product category is Biologics Contract Development and Manufacturing (CDMO). Its primary akta.pro industry code is HLAGABAC, Biologics (mAbs/Recombinant Proteins) CDMO, with a secondary code of HLAGABAK, Clinical Trial Material (CTM) Manufacturing & Supply CDMO. Its NAICS code is 325414 and its SIC code is 2836.